Expression and its clinical significance of ERCC1 in stage Ⅱ colorectal carcinoma / ERCC1在Ⅱ期结直肠癌中的表达及其临床意义

• Published in: Xi'an jiao tong da xue xue bao. Journal of Xi'an Jiaotong University (medical sciences). Yi xue ban no. 6; p. 898
• Main Authors: LIANG, Jing, Wen-an, WU, BAI Lu LIU Hui-juan, YANG, Yi-Ping, WANG, Qian, ZHANG Zhi-ce, LI, Tao
• Format: Journal Article
• Language: Chinese
• Published: Xi'an Xi'an Jiaotong University 01.01.2017
• Subjects: Chemotherapy; Clinical significance; Colorectal cancer; Medical prognosis; Metastasis
• ISSN: 1671-8259
• DOI: 10.7652/jdyxb201706022

Objective: To investigate the expression and clinical significance of excision repair cross complementing gene 1 (ERCC1) in colorectal carcinoma of stage Ⅱ and its clinical significance. Methods: We collected 56 cases of stage Ⅱ postoperative colorectal carcinoma tissue and detected ERCC1 expression with immunofluorescence technique. Statistical analysis was made with SPSS13.0 software. Results: ERCC1 expression was obviously lower in stage II postoperative colorectal carcinoma tissue than in normal tissue (P=0.01). In cancer tissue, ERCC1 expression in patients with relapse or metastasis was significantly lower than in those without (P=0.002); ERCC1 expression in patients with T3 was significantly higher than those with T4 (P＝0.044). ERCC1 expression had a positive correlation with the overall survival (OS) and disease-free survival (DFS) (both P＝0.000). In the group of high ERCC1 expression patients, five-year OS rate and DFS rate between patients who had received oxaliplatin-based adjuvant chemotherapy a